Provided herein are methods and compositions comprising a cannabinoid compound for providing neuroprotection and/or stimulating neuritogenesis. The cannabinoid compound can be a compound of Formula (I), wherein R.sup.1 is COOH or H, R.sup.2 is C.sub.3H.sub.7 or C.sub.5H.sub.11, R.sup.3 is H or Me, R.sup.4 and R.sup.5 are Me or (CH.sub.2).sub.2CH═C(CH.sub.3).sub.2, such as CBGA, a derivative thereof, a prodrug thereof, or combinations thereof, and can be used in the treatment of neurodegenerative diseases, or to promote neurite elongation and/or restore neurite formation in patients in need thereof.

A fluid system includes first microencapsulations encapsulating an active ingredient and a fluid holding the microencapsulations in suspension. A second active ingredient is in the fluid. The microencapsulations remain intact, rupture when exposed to friction, or dissolve upon passage of a period of time or based on another trigger event. A third active ingredient may be provided. A system is provided that includes a material embedded or coated with the provided fluid. The active ingredient may be a THC-free CBD isolate. An exemplary method provides exposure to a first active ingredient and a second active ingredient. Exposure to the first active ingredient and/or the second active ingredient may alleviate symptoms of arthritis, or repel insects.

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

This invention relates to compositions and methods for treating stammering/stuttering and Tourette syndrome (TS) in humans, using a formulation comprising of a combination of a Cannabis compound, or compounds.

This invention relates to compositions and methods for treating stammering/stuttering and Tourette syndrome (TS) in humans, using a formulation comprising of a combination of a Cannabis compound, or compounds.

The present disclosure relates to methods and compositions comprising cannabidiol (CBD) and a volatile anaesthetic, particularly isoflurane, useful for treating or preventing traumatic brain injury (TBI).

The present disclosure relates to methods and compositions comprising cannabidiol (CBD) and a volatile anaesthetic, particularly isoflurane, useful for treating or preventing traumatic brain injury (TBI).

Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of a-humulene and/or β-caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an Enterococcus faecium or an Enterococcus faecalis. Therapies are provided that utilize these formulations as anti-microbials, and provide for the combined use of two or more of the antibiotically active compounds.

Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of α-humulene and/or β-caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an Enterococcus faecium or an Enterococcus faecalis. Therapies are provided that utilize these formulations as anti-microbials, and provide for the combined use of two or more of the antibiotically active compounds.

Microemulsion beverages are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. The described microemulsion beverages may be thought of as modified oil-in-water (MOIHW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIHW microemulsion are modified with alcohol and can solubilize oil-soluble species, including cannabis extracts. The polar continuous “water” phase of the MOIHW microemulsion is modified with a sugar or sugar alcohol.